Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

These trials, including those from companies like Eisai and UCB, have demonstrated robust target ... JMP Securities also reiterated a Buy rating on the stock with a $83.00 price target. TipRanks ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play the stock amid the recent price decline ...

The underwritten offering of common stock at $31 per share comes shortly ... with the IPO expected to price sometime next week. Brand new biotech Eyconis, a spinout set up to advance the ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.